Boston-based Aktis Oncology (AKTS Proposed) upsized its IPO by 50 percent – by increasing the number of shares to 17.65 million – UP from 11.78 million – and kept the price range at $16.00 to $18.00 – to raise $300.05 million, if priced at the $17.00 mid-point of its range, according to an S-1/A filing early today – Wednesday, Jan. 7, 2025. The IPO’s original terms – disclosed on Monday – would have produced about $200.18 million in proceeds at the $17.00 mid-point price.
J.P. Morgan, BofA Securities, Leerink Partners and TD Cowen are the joint book-runners.
Aktis Oncology’s IPO is expected to price on Thursday night, Jan. 8, 2026, to trade Friday, Jan. 9, on the NASDAQ.
Under the new terms, Aktis Oncology would have a market cap of $892.88 million – assuming pricing at the $17.00 mid-point.
Aktis Oncology intends to use most of the IPO’s proceeds to fund clinical trials for its two leading drug candidates – Ac-AKY-1189 to treat bladder cancer tumors that express Nectin-4 and Ac-AKY-2519 to treat tumors that express B7-H3. (Incorporated in Delaware)
Financial Snapshot: Net loss of $60.65 million on revenue of $5.56 million for the 12 months that ended Sept. 30, 2025
(For more information, about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.